| Literature DB >> 35658976 |
Surya P Pandey1, Mackenzie J Bender1, Alex C McPherson2, Catherine M Phelps1, Luzmariel Medina Sanchez1, Mohit Rana1, Lee Hedden1, Kishan A Sangani3, Li Chen3, Jake H Shapira1, Magdalena Siller1, Chhavi Goel1, Elena F Verdú4, Bana Jabri5, Alexander Chang6, Uma R Chandran6, Steven J Mullett7, Stacy G Wendell7, Aatur D Singhi8, Jeremy S Tilstra9, Joseph F Pierre10, Gavin E Arteel11, Reinhard Hinterleitner1, Marlies Meisel12.
Abstract
The triggers that drive interferon-γ (IFNγ)-producing CD8 T cell (Tc1 cell)-mediated autoimmune hepatitis (AIH) remain obscure. Here, we show that lack of hematopoietic Tet methylcytosine dioxygenase 2 (Tet2), an epigenetic regulator associated with autoimmunity, results in the development of microbiota-dependent AIH-like pathology, accompanied by hepatic enrichment of aryl hydrocarbon receptor (AhR) ligand-producing pathobionts and rampant Tc1 cell immunity. We report that AIH-like disease development is dependent on both IFNγ and AhR signaling, as blocking either reverts ongoing AIH-like pathology. Illustrating the critical role of AhR-ligand-producing pathobionts in this condition, hepatic translocation of the AhR ligand indole-3-aldehyde (I3A)-releasing Lactobacillus reuteri is sufficient to trigger AIH-like pathology. Finally, we demonstrate that I3A is required for L. reuteri-induced Tc1 cell differentiation in vitro and AIH-like pathology in vivo, both of which are restrained by Tet2 within CD8 T cells. This AIH-disease model may contribute to the development of therapeutics to alleviate AIH.Entities:
Keywords: Lactobacillus reuteri; Tc1 cells; Tet2; aryl hydrocarbon receptor agonist; autoimmune hepatitis; liver microbiome
Mesh:
Substances:
Year: 2022 PMID: 35658976 DOI: 10.1016/j.chom.2022.05.006
Source DB: PubMed Journal: Cell Host Microbe ISSN: 1931-3128 Impact factor: 31.316